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RESEARCH IN CONTEXT  
Evidence before this study  
Gestational diabetes and gestational hypertensive disorders are common pregnancy complications 
associated with increased risks of perinatal mortality and morbidity, and seem to influence the risk of 
obesity in the offspring. Maternal obesity is a major risk factor for common pregnancy complications, 
and is also associated with an increased risk of obesity in the offspring. It is not clear whether 
gestational diabetes and gestational hypertensive disorders affect the risk of offspring obesity 
independently of the risk conferred by maternal obesity.  
Added value of this study  
We performed an individual participant data meta-analysis of 160757 mother-offspring pairs from 34 
prospective European or North-American contemporary pregnancy/birth cohorts. We observed that 
children born to mothers with gestational diabetes and gestational hypertension had a higher BMI and 
higher risk of being overweight throughout childhood. Pre-eclampsia was associated with a lower BMI 
in early-childhood. All associations were largely explained by maternal pre/early-pregnancy BMI.  
Implications of all the available evidence  
Lowering maternal risk of gestational diabetes, gestational hypertension and pre-eclampsia, though 
important in relation to maternal and fetal pregnancy outcomes, is unlikely to have a direct impact on 
offspring obesity. Preventive strategies for reducing childhood obesity should not focus on these 
pregnancy complications.  
 
SUMMARY  
Background: Gestational diabetes and gestational hypertensive disorders are associated with offspring 
obesity. The role of maternal adiposity in these associations remains unclear.  
Methods: In this individual participant data meta-analysis of 160757 mother-offspring pairs from 34 
prospective European or North-American pregnancy/birth cohorts, we assessed the associations of 
gestational diabetes, gestational hypertension and pre-eclampsia with childhood BMI and the risk of 
overweight and obesity throughout childhood. We explored to which extent any association was 
explained by maternal pre/early-pregnancy BMI.  
Findings: Gestational diabetes was associated with a higher risk of overweight throughout childhood 
(Odds Ratio (OR) 1·59 (95% Confidence Intervals (CI) 1·36, 1·86); OR 1·41 (95% CI 1·26, 1·57); OR 
1·32 (95% CI 0·99, 1·78) for early-, mid- and late-childhood, respectively) when compared to 
uncomplicated pregnancies. These associations attenuated towards the null following adjustment for 
maternal BMI. Likewise, gestational hypertension was associated with a higher risk of overweight 
throughout childhood, with the strongest association in late-childhood (OR 1·49 (95% CI 1·30, 1·70)), 
when compared to uncomplicated pregnancies. Additional adjustment for maternal BMI partly 
explained these associations. Pre-eclampsia was associated with a lower BMI in early-childhood only 
(difference in BMI-SDS - 0.05 SDS (95% CI - 0·09, - 0·01)), when compared to uncomplicated 
pregnancies. This association strengthened upon additional adjustment for maternal BMI.  
Interpretation: Our results suggest that lowering maternal risk of gestational diabetes and hypertensive 
disorders is unlikely to have a direct impact on offspring obesity.  
Funding: Funding sources for participating cohorts were declared as an acknowledgment.  
 
INTRODUCTION  
Gestational diabetes and gestational hypertensive disorders are common pregnancy complications with 
high global prevalences.1,2 These complications are major risk factors for maternal and fetal morbidity 
and mortality, and seem to be associated with obesity in offspring.1-6 Both fetal exposure to 
hyperglycemia due to gestational diabetes or altered utero-placental perfusion due to gestational 
hypertension and pre-eclampsia affect fetal nutrient supply.7,8 Alterations in the fetal supply line may 
influence fetal development, and trigger developmental adaptations in adipose tissue, neuroendocrine 
and metabolic function, which could predispose offspring to adiposity in later life.9  
Maternal obesity is a risk factor for gestational diabetes and gestational hypertensive disorders, and is 
also associated with an increased risk of obesity in offspring.10 Thus far, it is not clear whether 
gestational diabetes and gestational hypertensive disorders affect the risk of offspring obesity 
independently of the risk conferred by maternal obesity. Previous studies have shown that diabetes 
during pregnancy is associated with an increased risk of offspring obesity and higher fat mass levels, 
independent of maternal socio-demographic and lifestyle characteristics.11-17 Inconsistent findings 
were reported for the specific role of maternal obesity in these associations. Prospective cohort studies 
have assessed the relations of gestational hypertensive disorders with offspring blood pressure, but only 
few have also assessed the relation with offspring adiposity.18,19 A UK study reported that children of 
women who had either gestational hypertension or pre-eclampsia had higher risk of obesity at 9 years, 
whereas an Australian study found similar associations only in term born young adults of mothers with 
gestational hypertension, but not with pre-eclampsia.18,19  
Using individual participant data (IPD) from 160757 mother-offspring pairs, we assessed the strength 
and consistency of the associations of maternal gestational diabetes, gestational hypertension and pre-
eclampsia with the risks of offspring overweight and obesity throughout childhood. We also explored 
whether any observed association was independent of maternal pre-/early-pregnancy BMI.  
 
METHODS  
Inclusion criteria and participating cohorts  
We used data from an existing international collaboration on maternal obesity and childhood outcomes. 
Pregnancy and birth cohort studies were eligible for inclusion in this international collaboration if they 
were able to provide IPD on mothers with singleton live-born children born from 1989 onwards, and 
had information available on maternal pre/early-pregnancy BMI and birth weight and/or one measure 
of childhood BMI. We identified 50 potentially eligible cohorts from Europe, North America and 
Oceania from the existing collaborations or databases concerned with childhood health (EarlyNutrition 
Project, CHICOS Project, www.birthcohorts.net; last accessed July 2014). We invited all cohorts to 
participate, and 38 agreed and provided data on 274174 singleton births. For this study, we only 
included cohorts that were able to provide IPD on maternal gestational diabetes, gestational 
hypertension or pre-eclampsia, and childhood BMI measured at least once between age 2 and 17·9 
years. This resulted in 160757 mothers-offspring pairs available for analyses. Details on study selection 
process are provided in Supplemental Figure S1. Anonymized datasets were stored on a single central 
secured data server with access for the main analysts (BPG, SS). All studies were approved by their 
local institutional review boards/ ethics committees.  
Gestational diabetes, hypertensive disorders and pre/early-pregnancy BMI  
Information on gestational diabetes, gestational hypertension, pre-eclampsia and maternal BMI was 
obtained from medical records, through research assessments or was self-reported (cohort-specific 
information is shown in Supplemental Table S1). Where possible we used maternal pre-pregnancy BMI 
(<18·5, 18·5 - <25, 25 - <30, ≥30 kg/m2). Five cohorts (including 6,513 participants) did not have 
information about pre-pregnancy BMI but obtained BMI in early pregnancy (all assessed before or at 
20 weeks of gestation).  
 
Childhood BMI  
Data on childhood weight and height were mostly obtained through direct research assessments, with a 
small number of studies abstracting information about weight and height, or BMI, from medical 
records, report by parents/caregivers or self-reported (cohort-specific information is provided in 
Supplemental Table S1). We grouped BMI based on the age of children at assessment into 3 periods: 
early-childhood (2·0 – 4·9 years), mid-childhood (5·0 – 9·9 years), and late-childhood (10·0-17·9 years 
of age). If studies had multiple repeated measurements within the same age period, we used data 
collected at the oldest age. We calculated sex- and age-adjusted standard deviation scores (SDS) of 
childhood BMI using WHO reference growth charts (Growth Analyzer 4·0, Dutch Growth Research 
Foundation).20-23  
Childhood underweight, normal weight, overweight and obesity were defined based on the age- and 
sex- specific WHO criteria.20,21  
Covariates  
Information on covariates was mostly obtained by questionnaires (cohort-specific information is shown 
in Supplemental Table S1 and S2). As potential confounders other than maternal pre-pregnancy BMI, 
we considered maternal age (<25·0 years, 25-29·9 years, 30-34·9 years, ≥35·0 years), educational level 
(low, medium, high), ethnicity (European/White, non-European/non-White), parity (nulliparous, 
multiparous), smoking during pregnancy (yes, no), and offspring’s sex. We did not adjusted the 
primary analyses for offspring birth weight and gestational age at delivery, as these birth characteristics 
are likely to be mediators on the causal pathway and adjustment might introduce bias.24  
Statistical analysis  
We applied multilevel mixed effects models, taking into account clustering of participants within 
cohorts, to analyze simultaneously IPD from all cohorts.25 Our models were defined assuming a 
random intercept at cohort level, which allowed for differences in the intercepts between cohorts. First, 
we used multilevel linear mixed effects models to examine the associations of gestational diabetes, 
gestational hypertension or pre-eclampsia with BMI SDS in early-, mid-, and late-childhood. Second, 
we used multilevel binary logistic mixed effects models to examine the associations of these pregnancy 
complications with the risk of childhood underweight, overweight and obesity in the same age 
windows. Participants exposed to either gestational hypertension or pre-eclampsia were compared to 
those with none of these conditions, irrespective of their gestational diabetes status. Similarly, those 
exposed to gestational diabetes were compared to those with no gestational diabetes, irrespective of 
whether or not they had gestational hypertension or pre-eclampsia. For all analyses, we constructed an 
unadjusted model (Basic model), a model adjusted for offspring’s sex, maternal age, educational level, 
ethnicity, parity and smoking during pregnancy (Lifestyle characteristics model), and a model 
additionally adjusted for maternal pre/early-pregnancy BMI (Maternal BMI model). For the 
associations of pregnancy complications with the risk of childhood underweight, only the basic model 
was applied due to insufficient sample size. We tested potential interactions between each pregnancy 
complication and (i) offspring´s sex and (ii) maternal BMI, in their associations with childhood BMI. 
Since no consistent significant interactions were observed, no further stratified analyses were 
performed. The amount of missing data on covariates varied between cohorts (percentage missings per 
cohort given in Supplemental Table S2). To prevent exclusion of non-complete cases, we used missing 
values in these covariates as an additional group. We did not include information for a cohort for a 
specific categorical covariate, if information for this variable was available for less than 50% of the 
cohort sample. As sensitivity analysis, we performed a 2-stage random effects meta-analysis and 
examined whether there was evidence of heterogeneity between cohorts using the I2.25 Analyses were 
undertaken using the Statistical Package of Social Sciences version 21.0 for Windows (SPSS Inc, 
Chicago, IL, USA) and Review Manager ((RevMan) Version [5.3.5]. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014) software.  
 
RESULTS  
Subject characteristics  
The characteristics of the participants per cohort are presented in Table 1. Out of a total of 160757 
mothers, 2618 (1·7%) had gestational diabetes, 9755 (6·5%) had gestational hypertension, and 4836 
(3·3%) had pre-eclampsia. 30927 (19·7%) of the mothers were overweight and 12467 (7·9%) obese. 
Among offspring 5606 (6·6%), 24254 ( 20·1%) and 3699 (21·3 %) were overweight or obese in early-, 
mid-, and late-childhood, respectively. Cohort-specific information on childhood age at assessment and 
BMI is shown in Supplemental Table S4.  
Gestational diabetes and childhood body mass index  
Figure 1A shows that in the basic and lifestyle characteristics models, gestational diabetes was 
associated with a higher offspring BMI throughout childhood (difference in BMI-SDS from the 
lifestyle characteristics models: 0·11 SDS (95% Confidence Intervals (CI) 0·06, 0·16); 0·21 SDS (95% 
CI 0·16, 0·26); 0·08 SDS (95% CI -0·04, 0·21) in early-, mid- and late-childhood, respectively), as 
compared to uncomplicated pregnancies. After additional adjustment for maternal BMI, these 
associations fully attenuated towards the null. Similarly, gestational diabetes was associated with 
increased risks of overweight and obesity throughout childhood in the basic and lifestyle characteristics 
models, with the strongest association in early-childhood (OR 1·59 (95% Confidence Intervals (CI) 
1·36, 1·86) (Figure 1B). Adjustment for maternal BMI largely attenuated the effect estimates towards 
the null. Only the association of gestational diabetes with the risk of early childhood overweight and 
obesity remained significant (OR 1·35 (95% CI 1·15; 1·58)). Gestational diabetes tended to be 
associated with a lower risk of underweight throughout childhood in basic model. We were not able to 
examine adjustment for maternal BMI due to small numbers (Supplemental Table S4). Additional 
adjustment for gestational hypertension and pre-eclampsia did not affect the observed associations of 
gestational diabetes with childhood outcomes (data not shown).  
Gestational hypertensive disorders and childhood body mass index  
 
Figure 2A shows that, as compared to uncomplicated pregnancies, gestational hypertension was 
associated with a higher BMI throughout childhood in the basic and lifestyle characteristics models 
(differences in BMI-SDS in lifestyle characteristics model: 0·07 SDS (95% CI 0·03, 0·11); 0·13 SDS 
(95% CI 0·10, 0·17); 0·20 SDS (95% CI 0·14, 0·27) in early-, mid- and late-childhood, respectively). 
These associations were partly explained by maternal BMI (difference in BMI-SDS: 0·01 SDS (95% CI 
- 0·03, 0·06); 0·04 SDS (95% CI 0·01, 0·07); 0·07 SDS (95% CI 0·01, 0·13) in early-, mid- and late-
childhood, respectively). Gestational hypertension was also associated with higher risks of overweight 
and obesity throughout childhood. The strongest association was observed for late-childhood (OR 1·49 
(95% CI 1·30, 1·70)). Additional adjustment for maternal BMI largely attenuated these associations 
(Figure 2B). In the basic model, gestational hypertension was associated with a lower risk of childhood 
underweight at all ages (Supplemental Table S4).  
Pre-eclampsia was associated with a lower BMI in early-childhood in both the basic and lifestyle 
characteristics models (difference in BMI-SDS in lifestyle characteristics model: - 0.05 SDS (95% CI - 
0·09, - 0·01)) (Figure 3A). This inverse association strengthened upon additional adjustment for 
maternal BMI. In contrast, we observed a positive association of pre-eclampsia with BMI in mid- and 
late-childhood in the basic and lifestyle characteristics models (differences in BMI-SDS in lifestyle 
characteristics model: 0·10 SDS (95% CI 0·06, 0·13); 0·16 SDS (95% CI 0·03, 0·30) in mid- and late-
childhood, respectively). These associations fully attenuated after additional adjustment for maternal 
BMI. The associations of pre-eclampsia with overweight and obesity in mid- and late-childhood also 
fully attenuated after adjustment for maternal BMI (Figure 3B). In the basic model pre-eclampsia was 
associated with a higher risk of underweight in early-childhood only (Supplemental Table S4). We 
were unable to further explore adjustment for maternal BM because of small numbers. Similar 
associations between both gestational hypertension and pre-eclampsia with childhood outcomes were 
observed for all models when additionally adjusted for gestational diabetes (data not shown).  
2-stage meta-analyses as sensitivity analyses  
 
Analyses performed with 2-stage meta-analyses were consistent with those obtained from our main (1-
stage) meta-analyses (Supplemental Figures S2-10). We did not observe substantial heterogeneity 
between the cohorts (I2 range 0 to 40%, with 6 out of the 9 meta-analyses having I2 <25%; 
Supplemental Figures S2-10).  
 
DISCUSSION  
Results from our IPD analysis of 160757 mothers and children from 18 different countries from Europe 
and North America, demonstrated that children born to mothers with gestational diabetes and 
gestational hypertension had a higher BMI and higher risk of being overweight or obese throughout 
childhood, whereas pre-eclampsia was associated with a lower BMI in early-childhood. These 
associations were largely explained by maternal pre/early-pregnancy BMI.  
Interpretation of main findings  
Gestational diabetes, gestational hypertension and pre-eclampsia affect substantial numbers of 
pregnancies and are associated with a wide range of adverse maternal and fetal pregnancy outcomes.1-
3 Gestational diabetes may lead to fetal overnutrition as a result of maternal hyperglycemia during 
pregnancy.7 Gestational hypertension and pre-eclampsia are related to placental dysfunction, which 
may lead to impaired fetal nutrient supply.8,26 Both conditions may subsequently induce permanent 
changes in offspring body composition, neuroendocrine systems and metabolic functions, which 
predispose offspring to an increased risk of obesity in later life.9 Our aim was to explore if gestational 
diabetes and gestational hypertensive disorders affect the risk of offspring obesity independently of the 
risk conferred by maternal obesity. Disentangling the independent role of these maternal pregnancy 
complications on childhood obesity risk is important for development of future childhood obesity 
prevention strategies.  
Results from two systematic reviews of 12 and 9 published cohort studies suggested that maternal 
diabetes during pregnancy was associated with a higher offspring BMI . These associations were no 
longer present in single studies that adjusted for maternal pre-pregnancy BMI.6,27 Recently, several 
prospective observational studies reported inconsistent findings for the association of gestational 
diabetes with offspring BMI after adjustment for maternal BMI.11-17,28-30 An older prospective 
cohort study of 280866 Swedish men recruited from 1973 to 1988, suggested that diabetes during 
pregnancy, including gestational diabetes and pre-existing diabetes, was associated with a higher BMI 
at the age of 18 years. This association was independent of maternal BMI.17 In contrast, we observed 
that children of mothers with gestational diabetes had a higher BMI throughout childhood, but this 
association was largely explained by maternal pre/early-pregnancy BMI. This different finding might 
be explained by differences in study populations as our IPD included contemporary cohorts only with 
newer screening and treatment strategies, and mainly included offspring measurements at younger ages. 
We observed the strongest association of gestational diabetes with offspring obesity in early-childhood. 
This may be explained by tracking of birth size.31.32 Consistent with our findings, treatment of mild 
gestational diabetes was found to be beneficial for neonatal outcomes, but did not influence offspring 
obesity risk at age 5-10 years in a multicenter randomized controlled trial.33 Using the diagnosis of 
gestational diabetes may insufficiently reflect glycemic status during pregnancy. Maternal glucose 
levels below current diagnostic criteria of diabetes, are linearly and positively associated with adverse 
perinatal outcomes.31,34 However, several studies showed that maternal glucose levels during 
pregnancy were not associated with offspring BMI in early childhood, after adjustment for maternal 
BMI.35,36 Thus, our findings strongly suggest that the association of gestational diabetes with higher 
BMI in the offspring is largely explained by maternal BMI.  
Few studies have examined the association of gestational hypertensive disorders with childhood 
adiposity. Data from a UK prospective cohort study of 6343 mother-offspring pairs found a positive 
association of gestational hypertension with childhood adiposity at age 9, which attenuated after 
adjustment for parental BMI.18 This study also found inverse associations of pre-eclampsia with 
offspring lean mass and adiposity at age 9 after adjustment for parental BMI.18 In contrast, an 
Australian cohort study of 1151 mother-offspring pairs born at term showed that offspring of mothers 
with gestational hypertension had higher BMI and risk of overweight and obesity at 20 years, 
independently of maternal  
BMI.19 No association of pre-eclampsia with offspring BMI was present.19 In the current study, we 
observed that gestational hypertension was associated with a higher BMI and risk of overweight 
throughout childhood, but this association was also largely explained by maternal BMI. Pre-eclampsia 
was associated with a lower BMI in early-childhood, and this inverse association was stronger after 
adjustment for maternal BMI. In later childhood, no associations independent of maternal BMI were 
present. This might be explained by tracking of lower birth size into early-childhood among children of 
mothers with pre-eclampsia due to placental dysfunction and fetal growth restriction.37 Further studies 
aiming at detailed assessment of maternal blood pressure and placental vascular function, which 
provides details on the severity of the disease, may provide more insight into the effects of pre-
eclampsia on childhood adiposity development.  
Our observations that the associations of gestational diabetes and gestational hypertensive disorders 
with offspring obesity largely dependent on maternal BMI are important from an etiological and 
preventive perspective. Interventions to reduce the risk of pregnancy complications or improve the 
effectiveness of their treatment may be important in relation to a range of problems for the mother and 
child, but they are unlikely to influence directly the development of obesity in offspring.  
Strengths and limitations  
Major strengths of our study are the large sample of contemporary populations reflecting current 
diagnosis and treatment policies and the use individual participant data from a wide selection of 
existing studies to reduce the risk of publication bias. We were able to adjust for a range of relevant 
confounding factors, with a particular focus on maternal pre-pregnancy BMI. We are aware that our 
study cannot overcome potential limitations of individual studies in terms of their design and conduct, 
differences in measurements and definitions of exposure and outcome data, variation in missing data 
and loss to follow up. .Especially, the prevalence of gestational diabetes in our sample was relatively 
low and varied substantially between cohorts, which might suggest underascertainment of this 
condition. However, our 2-stage meta-analysis suggested low heterogeneity between studies. We have 
no information on how any of the pregnancy complications were treated. Effective treatment that 
reduced circulating glucose and blood pressure during pregnancy may lead to weaker associations of 
these conditions with offspring obesity. However, this reflects contemporary clinical practice. Finally, 
due to the observational design, residual confounding cannot be excluded.  
 
CONCLUSIONS  
The associations of gestational diabetes, gestational hypertension and pre-eclampsia with childhood 
obesity are largely explained by maternal pre/early-pregnancy BMI. Interventions focused on 
prevention or treatment of these pregnancy complications, though important for other maternal and 
fetal pregnancy outcomes, are unlikely to have a direct impact on offspring BMI.  
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Table 1. Characteristics of the participating pregnancy and birth cohorts (n=160757)a,b  
Cohort name,  
number of participants,  
birth years (country)  
Gestational  
diabetes  
Gestational 
hypertension  
Pre-
eclampsia  
Early 
childhood (2·0-
4·9y)  
Mid 
childhood 
(5·0-9·9y)  
Late 
childhood 
(10·0-17·9y)  
Body mass index (SDS)  Overweight and 
obesity  
Body mass 
index (SDS)  
Overweight 
and obesity  
Body mass index 
(SDS)  
Overweight and 
obesity  
ABCD, n=5512, 2003-
2004 (The 
Netherlands)  
120 
(2·2)  
1045 
(19·0)  
233 
(4·2)  
0·3 (-1·5, 
2·4)  
213 (4·5) 0·1 (-
1·7, 
2·4)  
768 
(17·1)  
NA  NA  
ALSPAC, n=9041, 
1991-1992 (United 
Kingdom)  
77 
(0·9)  
1282 
(14·5)  
170 
(1·9)  
0·6 (-1·0, 
2·5)  
77 (6·5)  0·2 (-
1·6, 
2·7)  
2113 
(26·4)  
0·2 (-
1·9, 
2·5)  
2063 (26·4)  
AOB/F, n=1672,  
2008-2010 (Canada)  
71 
(4·2)  
118 
(7·1)  
104 
(6·2)  
0·2 (-2·3, 
2·7)  
96 (5·7)  NA  NA  NA  NA  
BAMSE, n=3329,  
1994-1996 (Sweden)  
56 
(1·7)  
NA  55 
(1·7)  
0·6 (-0·9, 
2·5)  
187 (6·5) 0·5 (-
1·2, 
2·6)  
799 
(31·2)  
0·1 (-
1·7, 
2·0)  
425 (16·9)  
BIB, n=983, 2007-
2010 (United 
Kingdom)  
100 
(10·2)  
51 
(5·3)  
13 
(1·4)  
0·5 (-1·4, 
2·6)  
74 (7·5)  NA  NA  NA  NA  
Co.N.ER, n=528,  
2004-2005 (Italy)  
14 
(2·7)  
20 
(3·8)  
12 
(2·3)  
0·3 (-2·3, 
2·9)  
47 (9·7)  0·7 (-
1·3, 
2·9)  
102 
(35·5)  
NA  NA  
DNBC, n=40349,  
1996-2002 (Denmark)  
273 
(0·7)  
1878 
(4·7)  
1380 
(3·4)  
NA  NA  0 (-
1·9, 
2·1)  
6304 
(15·6)  
NA  NA  
EDEN, n=1361,  
2003-2005 (France)  
92 
(6·8)  
67 
(4·9)  
30 
(2·2)  
0·3 (-1·4, 
2·0)  
27 (2·2)  0 (-
1·5, 
2·0)  
147 
(12·9)  
NA  NA  
FCOU, n=2332,  
1993-1996 (Ukraine)  
5 (0·2)  367 
(15·7)  
148 
(6·3)  
0·5 (-1·9, 
3·1)  
140 
(10·6)  
0 (-
2·0, 
2·0)  
124 
(12·6)  
-0·1 (-
2·0, 
1·8)  
75 (8·9)  
GASPII, n=570,  
2003-2004 (Italy)  
25 
(4·4)  
28 
(4·9)  
5 (0·9) 0·7 (-1·1, 
2·9)  
52 (9·7)  0·7 (-
1·4, 
2·7)  
172 
(37·1)  
NA  NA  
GECKO Drenthe, 
n=2119, 2006-2007  
(The Netherlands)  
72 
(3·4)  
209 
(11·0)  
46 
(2·4)  
NA  NA  0·4 (-
1·2, 
2·4)  
465 
(21·9)  
NA  NA  
GENESIS, n=2143,  
2003-2004 (Greece)  
30 
(1·4)  
NA  NA  0·8 (-1·2, 
3·6)  
297 
(14·6)  
1·0 (-
1·5, 
3·9)  
45 
(42·1)  
NA  NA  
GENERATION R, 
n=7550, 2002-2006  
(The Netherlands)  
80 
(1·1)  
274 
(4·0)  
149 
(2·3)  
0·3 (-1·5, 
2·5)  
220 (5·1) 0·3 (-
1·5, 
2·7)  
1849 
(27·4)  
0·4 (-
1·5, 
2·6)  
160 (30·0)  
GENERATION XXI, 
n=5921,  
2005-2006 (Portugal)  
390 
(6·6)  
135 
(2·3)  
90 
(1·5)  
0·5 (-1·3, 
3·1)  
485 
(10·4)  
0·6 (-
1·4, 
3·2)  
2015 
(38·0)  
NA  NA  
GINIplus, n=2313,  
1995-1998 (Germany)  
61 
(2·6)  
NA  NA  0·1 (-1·7, 
2·0)  
53 (2·4)  0 (-
1·8, 
1·9)  
227 
(10·6)  
0 (-1·9, 
2·1)  
365 (16·0)  
 
 
 
 
 
 
 
Table 1. Characteristics of the participating pregnancy and birth cohorts (n=160757)a (continued)  
Cohort name,  
number of 
participants,  
birth years (country)  
Gestational  
diabetes  
Gestational 
hypertension  
Pre-
eclampsia  
Early childhood 
(2·0-4·9 y)  
Mid 
childhood 
(5·0-9·9y)  
Late 
childhood 
(10·0-17·9y)  
Body mass index (SDS)  Overweight and 
obesity  
Body mass 
index (SDS)  
Overweight 
and obesity  
Body mass index 
(SDS)  
Overweight and 
obesity  
HUMIS, n=970,  
2003-2008 (Norway)  
5 (0·5)  37 
(3·8)  
70 
(7·2)  
0·3 (-1·8, 
2·4)  
53 (6·0)  0·0 (-
2·0, 
2·3)  
63 
(17·6)  
NA  NA  
INMA, n=1933,  
1997-2008 (Spain)  
191 
(11·3)  
58 
(3·0)  
4 (0·9) 0·5 (-1·2, 
2·8)  
143 (8·2)  0·6 (-
1·4, 
3·3)  
503 
(37·6)  
0·3 (-
1·6, 
2·5)  
79 (25·3)  
KOALA, n=2061, 
2000-2002 (The 
Netherlands)  
21 
(1·0)  
72 
(3·5)  
26 
(1·3)  
-0·1 (-
2·0, 1·9)  
17 (1·7)  -0·2 (-
2·2, 
1·8)  
199 
(11·3)  
-0·2 (-
2·1, 
2·2)  
19 (18·1)  
Krakow Cohort, 
n=424,  
2000-2003 (Poland)  
18 
(4·2)  
19 
(4·5)  
0 (0·0) 0 (-2·2, 
2·3)  
11 (4·1)  0·2 (-
1·8, 
2·6)  
90 
(26·5)  
NA  NA  
LISAplus, n=1584,  
1997-1999 
(Germany)  
58 
(3·7)  
NA  NA  0 (-1·7, 
1·9)  
33 (2·3)  -0·1 (-
1·8, 
1·8)  
140 
(9·9)  
0 (1·8, 
2·1)  
236 (15·2)  
MoBa, n=55008,  
1999-2009 (Norway)  
418 
(0·8)  
3131 
(5·7)  
2023 
(3·7)  
0·4 (-1·8, 
2·5)  
2456 
(6·1)  
0·1 (-
2·0, 
2·3)  
6793 
(19·5)  
NA  NA  
NINFEAb, n=1726,  
2005-2010 (Italy)  
132 
(7·7)  
136 
(7·9)  
44 
(2·6)  
0·1 (-2·3, 
2·5)  
86 (5·1)  0 (-
2·2, 
2·4)  
90 
(21·2)  
NA  NA  
PÉLAGIE, n=738,  
2002-2005 (France)  
21 
(2·8)  
24 
(3·3)  
8 (1·1) 0·1 (-1·8, 
1·9)  
15 (2·0)  NA  NA  NA  NA  
PIAMA, n=1815, 
1996-1997 (The 
Netherlands)  
19 
(1·0)  
179 
(9·9)  
46 
(2·5)  
0·7 (-1·2, 
2·5)  
78 (8·9)  0·1 (-
1·6, 
2·4)  
325 
(20·0)  
-0·2 (-
1·7, 
1·8)  
77 (10·0)  
Piccolipiù, n=687,  
2011-2015 (Italy)  
69 
(10·1)  
24 
(3·5)  
6 (0·9) 0·3 (-2·1, 
2·5)  
40 (5·8)  NA  NA  NA  NA  
Project Viva, 
n=1389,  
1999-2002 (United 
States)  
64 
(4·7)  
85 
(6·3)  
46 
(3·4)  
0·7 (-1·0, 
2·7)  
87 (7·1)  0·4 (-
1·4, 
3·0)  
328 
(30·8)  
0·4 (-
1·5, 
3·7)  
8 (25·8)  
REPRO_PL, n=291,  
2007-2011 (Poland)  
13 
(4·5)  
17 
(5·8)  
0 (0·0) 0·3 (-2·2, 
2·5)  
19 (6·9)  0·6 (-
1·5, 
3·6)  
19 
(38·8)  
NA  NA  
RHEA, n=740,  
2007-2008 (Greece)  
60 
(8·8)  
35 
(5·2)  
5 (0·7) 0·6 (-1·1, 
3·6)  
91 (12·3)  NA  NA  NA  NA  
ROLO, n=283,  
2007-2011 (Ireland)  
10 
(3·5)  
NA  NA  0·2 (-1·7, 
2·6)  
19 (6·7)  NA  NA  NA  NA  
SCOPE BASELINE, 
n=1046, 2008-2011 
(Ireland)  
NA  129 
(12·3)  
35 
(3·3)  
0·6 (-1·0, 
2·3)  
62 (5·9)  NA  NA  NA  NA  
 
 
 
 
 
 
 
 
Table 1. Characteristics of the participating pregnancy and birth cohorts (n=160757)a (continued)  
Cohort name,  
number of 
participants,  
birth years (country)  
Gestational  
diabetes  
Gestational 
hypertension  
Pre-
eclampsia  
Early childhood 
(2·0-4·9 y)  
Mid 
childhood 
(5·0-9·9y)  
Late 
childhood 
(10·0-17·9y)  
Body mass index (SDS)  Overweight and 
obesity  
Body mass 
index (SDS)  
Overweight 
and obesity  
Body mass index 
(SDS)  
Overweight  
and obesity  
SEATON, n=872, 
1998-1999 (United 
Kingdom)  
NA  119 
(13·9)  
16 
(2·1)  
0·7 (-0·9, 
2·7)  
36 (8·1)  0·6 (-
1·1, 
2·8)  
55 
(19·8)  
0·4 (-
1·6, 2·6)  
192 (32·9)  
Slovak PCB study, 
n=524, 2002-2004 
(Slovakia)  
3 (0·6) 54 
(12·4)  
NA  1·9 (-2·4, 
5·3)  
222 
(48·2)  
0·3 (-
1·7, 
3·3)  
123 
(31·0)  
NA  NA  
STEPS, n=297, 
2008-2010 (Finland)  
20 
(6·7)  
NA  NA  0·5 (-1·2, 
2·2)  
13 (4·4)  NA  NA  NA  NA  
SWS, n=2646, 1998-
2007 (United 
Kingdom)  
30 
(1·1)  
162 
(6·1)  
72 
(2·7)  
0·5 (-1·3, 
2·6)  
157 (6·2)  0·2 (-
1·5, 
2·5)  
396 
(22·0)  
NA  NA  
 
aValues are expressed as medians (95% range) or numbers of subjects (valid %). NA, not available.  
b Subset of participants with follow-up completed at 4 years of child’s age by the time of data transfer (March 2015).  
 
Figure 1. Associations of gestational diabetes with offspring BMI outcomes in early, mid, and late 
childhood.a aValues are regression coefficients (95% confidence intervals) from multilevel linear 
mixed effects models and odds ratios (95% confidence intervals) from multilevel binary logistic 
models that reflect differences in early childhood (2·0 to 4·9 years), mid childhood (5·0 to 9·9 years) 
and late childhood (10·0 to 17·9 years) BMI SDS and risk of overweight and obesity, respectively, for 
children born to mothers with gestational diabetes, as compared with the reference group (children born 
to mothers with an uncomplicated pregnancy). Lifestyle characteristics models are adjusted for 
offspring’s sex, maternal age, educational level, ethnicity, parity, and smoking during pregnancy. 
Maternal BMI models are additionally adjusted for maternal pre/early-pregnancy BMI.  
 
Figure 2. Associations of gestational hypertension with offspring BMI outcomes in early, mid, and late 
childhood.a aValues are regression coefficients (95% confidence intervals) from multilevel linear 
mixed effects models and odds ratios (95% confidence intervals) from multilevel binary logistic 
models that reflect differences in early childhood (2·0 to 4·9 years), mid childhood (5·0 to 9·9 years) 
and late childhood (10·0 to 17·9 years) BMI SDS and risk of overweight and obesity, respectively, for 
children born to mothers with gestational hypertension, as compared with the reference group (children 
born to mothers with an uncomplicated pregnancy). Lifestyle characteristics models are adjusted for 
offspring’s sex, maternal age, educational level, ethnicity, parity, and smoking during pregnancy. 
Maternal BMI models are additionally adjusted for maternal pre/early-pregnancy BMI.  
 
Figure 3. Associations of pre-eclampsia with offspring BMI outcomes in early, mid, and late 
childhood.a aValues are regression coefficients (95% confidence intervals) from multilevel linear 
mixed effects models and odds ratios (95% confidence intervals) from multilevel binary logistic 
models that reflect differences in early childhood (2·0 to 4·9 years), mid childhood (5·0 to 9·9 years) 
and late childhood (10·0 to 17·9 years) BMI SDS and risk of overweight and obesity, respectively, for 
children born to mothers with pre-eclampsia, as compared with the reference group (children born to 
mothers with an uncomplicated pregnancy). Lifestyle characteristics models are adjusted for 
offspring’s sex, maternal age, educational level, ethnicity, parity, and smoking during pregnancy. 
Maternal BMI models are additionally adjusted for maternal pre/early-pregnancy BMI.  
